Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.lfs.2020.118142 http://scihub22266oqcxt.onion/10.1016/j.lfs.2020.118142 32712300!7377983!32712300     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Life+Sci 2020 ; 257 (ä): 118142 Nephropedia Template TP {{tp|p=32712300|t=2020. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future |pdf=|usr=}}{{32712300}} gab.com Text The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future JO: Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32712300 #FOAvip Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some professional groups are concerned about whether the use of RAAS inhibitors affects the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in COVID-19 patients. In this review, we summarize preclinical and clinical studies to investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or patients. We also analyzed whether the use of these drugs affects the risk of SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally, the review suggests that current evidence does not support the concerns. Twit Text FOAVip The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future ????Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32712300 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32712300 #FOAvip English Wikipedia <ref>{{Cite pmid|32712300}}</ref> The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future #MMPMID32712300 Zhang J; Wang M; Ding W; Wan J Life Sci 2020[Sep]; 257 (ä): 118142 PMID32712300show ga Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some professional groups are concerned about whether the use of RAAS inhibitors affects the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in COVID-19 patients. In this review, we summarize preclinical and clinical studies to investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or patients. We also analyzed whether the use of these drugs affects the risk of SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally, the review suggests that current evidence does not support the concerns. |Angiotensin II Type 1 Receptor Blockers/metabolism[MESH] |Angiotensin Receptor Antagonists/metabolism/*pharmacology[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/metabolism[MESH] |Betacoronavirus/*drug effects/immunology/metabolism[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/immunology/metabolism[MESH] |Humans[MESH] |Inflammation/immunology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/genetics/*metabolism[MESH] |Pneumonia, Viral/drug therapy/immunology/metabolism[MESH] |Renin-Angiotensin System/physiology[MESH] |Risk Factors[MESH]The interaction of RAAS inhibitors with COVID-19: Current progress, pe(epmc).pdf DeepDyve Pubget Overpricing